1. Pink Sheet

EU Regulators Eye Social Media For Real-World Data Insights

 
• By Vibha Sharma

As drug companies continue to explore the use of social media data to support their submissions, a panel of EU regulators have drawn up a seven-point action plan to help evaluate the usefulness and impact of such data in regulatory decision-making.

High angle view of African American woman holding cellphone with blank screen on blurred foreground
Social Media Platforms Can Capture Patient Experience Data (Shutterstock)
Key Takeaways
  • The EU Big Data Steering Group (BDSG) has issued a report on the potential advantages and challenges of leveraging social media data in regulatory decision-making.
  • The report recommends a series of actions for EU regulators to help establish the value of social media data and enable its use in medicines regulation.
  • The BDSG says it is crucial for regulators to tackle the issue given the increasing trend of companies exploring the use of social media data to support their regulatory submissions.
  • European Medicines Agency’s regulatory pipeline database shows that companies have used, or plan to use, social media data for patient recruitment, data collection, to justify study designs and for pharmacovigilance activities.

Ongoing efforts in the EU to expand the availability of real-world data (RWD) sources for regulators have resulted in a growing

It has prompted EU Big Data Steering Group (BDSG) to recommend a range of actions, including launching proof-of-concept studies, to help evaluate if social media data can

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from R&D

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.